Immunocore Holdings plc (NASDAQ:IMCR) Position Trimmed by Bank of America Corp DE

Bank of America Corp DE reduced its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 33.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 189,577 shares of the company's stock after selling 95,362 shares during the quarter. Bank of America Corp DE owned approximately 0.38% of Immunocore worth $5,593,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. increased its holdings in Immunocore by 3.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company's stock valued at $197,657,000 after acquiring an additional 200,373 shares in the last quarter. Primecap Management Co. CA grew its holdings in shares of Immunocore by 8.0% during the fourth quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock worth $78,722,000 after buying an additional 196,530 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Immunocore by 1.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company's stock worth $64,533,000 after buying an additional 29,832 shares in the last quarter. Groupama Asset Managment purchased a new stake in shares of Immunocore during the fourth quarter worth about $17,700,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Immunocore during the fourth quarter worth about $5,697,000. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Stock Up 11.3%

Shares of NASDAQ IMCR traded up $3.55 during trading on Thursday, reaching $35.04. 1,069,510 shares of the stock were exchanged, compared to its average volume of 391,875. The business's 50-day moving average price is $29.12 and its 200 day moving average price is $29.98. Immunocore Holdings plc has a twelve month low of $23.15 and a twelve month high of $49.05. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -36.88 and a beta of 0.75.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.45. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business had revenue of $125.13 million for the quarter, compared to analysts' expectations of $108.82 million. During the same period in the previous year, the company posted ($0.49) earnings per share. The business's revenue for the quarter was up 33.6% compared to the same quarter last year. As a group, equities analysts forecast that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on IMCR shares. Oppenheimer lifted their price target on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Deutsche Bank Aktiengesellschaft started coverage on shares of Immunocore in a report on Tuesday. They set a "buy" rating and a $65.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $100.00 price target on shares of Immunocore in a report on Wednesday, March 12th. JPMorgan Chase & Co. lowered their price target on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a report on Monday, April 14th. Finally, Mizuho lowered their price target on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a report on Monday, April 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Immunocore presently has an average rating of "Moderate Buy" and an average price target of $58.89.

Insider Transactions at Immunocore

In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the purchase, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This represents a 60.40% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.40% of the company's stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.